The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Open accessAbstract
Purpose: To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials. Methods: An International Harmonization Project (IHP) was convened to discuss standardization of clinical trial parameters in lymphoma. An imaging subcommittee developed consensus recommendations based on published PET literature and the collective expertise of its members in the use of PET in lymphoma. Only recommendations subsequently endorsed by all IHP subcommittees were adopted. Recommendations: PET after completion of therapy should be performed at least 3 weeks, and preferably at 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or chemoradiotherapy. Visual assessment alone is adequate for interpreting PET findings as positive or negative when assessing response after completion of therapy. Mediastinal blood pool activity is recommended as the reference background activity to define PET positivity for a residual mass ≥ 2 cm in greatest transverse diameter, regardless of its location. A smaller residual mass or a normal sized lymph node (ie, ≤ 1 × 1 cm in diameter) should be considered positive if its activity is above that of the surrounding background. Specific criteria for defining PET positivity in the liver, spleen, lung, and bone marrow are also proposed. Use of attenuation-corrected PET is strongly encouraged. Use of PET for treatment monitoring during a course of therapy should only be done in a clinical trial or as part of a prospective registry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationOllinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Self-citationHutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Shankar, L. K., Hoffman, J. M., Bacharach, S. L., Graham, M. M., Karp, J. S., Lammertsma, A. A., Larson, S. M., Mankoff, D. A., Siegel, B. A., den Abbeele, A. V., et al. (2006) · PubMed · Cited by 674
Self-citationProcedure guideline for tumor imaging with F-18 FDG PET/CT
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hübner, K. F., et al. (2006) · Cited by 620
Self-citationJerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Schöder, H., Noy, A., Gönen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., & Yeung, H. W. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.072 · Cited by 491
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Self-citationUtility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.-A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2778 · Cited by 437
Cited by
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationFrom RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“Progression in the lungs, particularly in the presence of potential inflammation or infection while a patient is on treatment, should be viewed with great caution, as discussed in the revised response criteria in lymphoma (32,33).”
BackgroundInfluentialFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2961-x · Cited by 3,303
“Some criteria have already been proposed [78, 79].”
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Boellaard, R., O’Doherty, M. J., Weber, W. A., Mottaghy, F. M., Lonsdale, M. N., Stroobants, S. G., Oyen, W. J. G., Kotzerke, J., Hoekstra, O. S., Pruim, J., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1297-4 · Cited by 1,326
Self-citationStandards for PET Image Acquisition and Quantitative Data Analysis
Boellaard, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057182 · Cited by 902
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Report on the First International Workshop on interim-PET scan in lymphoma
Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., & Haioun, C. (2009) · Leukemia & Lymphoma · doi:10.1080/10428190903040048 · Cited by 754
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Self-citationKinahan, P. E., & Fletcher, J. W. (2010) · Seminars in Ultrasound, CT and MRI · doi:10.1053/j.sult.2010.10.001 · Cited by 631
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6394 · Cited by 542
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Boellaard, R., Oyen, W. J. G., Hoekstra, C. J., Hoekstra, O. S., Visser, E. P., Willemsen, A. T., Arends, B., Verzijlbergen, F. J., Zijlstra, J., Paans, A. M., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0874-2 · Cited by 396
Self-citationLin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J.-N., Rahmouni, A., & Meignan, M. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042093 · Cited by 394
Raemaekers, J. M. M., André, M. P. E., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., Brice, P., Fermé, C., van der Maazen, R., Gotti, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.9298 · Cited by 387
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx097 · Cited by 369
Self-citation18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Barrington, S. F., Qian, W., Somer, E. J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Højgaard, L., Federico, M., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1490-5 · Cited by 348
Moskowitz, C. H., Schöder, H., Teruya-Feldstein, J., Sima, C., Iasonos, A., Portlock, C. S., Straus, D., Noy, A., Palomba, M. L., O'Connor, O. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5942 · Cited by 326
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Xiang, L., Qiao, Y., Nie, D., An, L., Lin, W., Wang, Q., & Shen, D. (2017) · Neurocomputing · doi:10.1016/j.neucom.2017.06.048 · Cited by 308
The role of FDG-PET scans in patients with lymphoma
Seam, P., Juweid, M. E., & Cheson, B. D. (2007) · Blood · doi:10.1182/blood-2007-06-097238 · Cited by 304
Self-citationFDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Barrington, S. F., & Kluge, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3690-8 · Cited by 281
Role of Functional Imaging in the Management of Lymphoma
Cheson, B. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5225 · Cited by 280
Self-citationPET/MRI: Where might it replace PET/CT?
Ehman, E. C., Johnson, G. B., Villanueva‐Meyer, J. E., Cha, S., Leynes, A. P., Larson, P. E. Z., & Hope, T. A. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25711 · Cited by 271
Martinez-Outschoorn, U. E., Lin, Z., Trimmer, C., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16585 · Cited by 270
Assessing Tumor Response to Therapy
Weber, W. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057174 · Cited by 269
Self-citationFowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L., Hagemeister, F. B., McLaughlin, P., Kwak, L. W., Romaguera, J. E., Fanale, M. A., Fayad, L. E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70455-3 · Cited by 264
Imaging in staging of malignant lymphoma: a systematic review
Kwee, T. C., Kwee, R. M., & Nievelstein, R. A. J. (2008) · Blood · doi:10.1182/blood-2007-07-101899 · Cited by 264
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Véra, P., Tilly, H., Siegel, B. A., Gallamini, A., Casasnovas, R.-O., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2435-6 · Cited by 255
Self-citationTerasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T., & Nagai, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0861 · Cited by 254
Feasibility of state of the art PET/CT systems performance harmonisation
Kaalep, A., Sera, T., Rijnsdorp, S., Yaqub, M., Talsma, A., Lodge, M. A., & Boellaard, R. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3977-4 · Cited by 160
Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis
de Langen, A. J., Vincent, A., Velasquez, L. M., van Tinteren, H., Boellaard, R., Shankar, L. K., Boers, M., Smit, E. F., Stroobants, S., Weber, W. A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095299 · Cited by 157
Self-citationHasenclever, D., Kurch, L., Mauz-Körholz, C., Elsner, A., Georgi, T., Wallace, H., Landman-Parker, J., Moryl-Bujakowska, A., Cepelová, M., Karlén, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2715-9 · Cited by 157
Büsing, K. A., Schönberg, S. O., Brade, J., & Wasser, K. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.10.014 · Cited by 111
Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology
Ziai, P., Hayeri, M. R., Salei, A., Salavati, A., Houshmand, S., Alavi, A., & Teytelboym, O. M. (2016) · RadioGraphics · doi:10.1148/rg.2016150102 · Cited by 106
Kluge, R., Chavdarova, L., Hoffmann, M., Kobe, C., Malkowski, B., Montravers, F., Kurch, L., Georgi, T., Dietlein, M., Wallace, W. H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149072 · Cited by 56
Self-citationFDG PET/CT-based response assessment in malignancies
Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023) · RadioGraphics · doi:10.1148/rg.220122 · Cited by 53
“FDG PET was included in the 2007 International Harmonization Project (IHP) criteria for assessing response in HL and NHL (31,32), which recommended visual interpretation of the PET images and comparison of the lesion avidity with the mediastinal blood pool avidity to determine response.”
InfluentialFurth, C., Amthauer, H., Hautzel, H., Steffen, I. G., Ruf, J., Schiefer, J., Schönberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq557 · Cited by 43
Self-citationObserver Variation in Interpreting 18F-FDG PET/CT Findings for Lymphoma Staging
Hofman, M. S., Smeeton, N. C., Rankin, S. C., Nunan, T., & O'Doherty, M. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064121 · Cited by 41
PET/CT mediastinal and liver FDG uptake: Effects of biological and procedural factors
Malladi, A., Viner, M., Jackson, T., Mercier, G., & Subramaniam, R. M. (2013) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12015 · Cited by 35
Ceriani, L., Barrington, S., Biggi, A., Malkowski, B., Metser, U., Versari, A., Martelli, M., Davies, A., Johnson, P. W., Zucca, E., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2339 · Cited by 26
Mittal, B., Kuruva, M., Abrar, M., Kashyap, R., & Bhattacharya, A. (2012) · Indian Journal of Nuclear Medicine · doi:10.4103/0972-3919.108835 · Cited by 24
Metadata
- Authors
- Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R. J., Weber, W. A., Reske, S. N., Schwaiger, M., Schwartz, L. H., Zijlstra, J. M., Siegel, B. A., & Cheson, B. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 571-578
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142724147
- Cited by
- 1,335
- References
- 29
- FWCI
- 76.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.